Ruifeng Xue
About
In The Last Decade
Ruifeng Xue
24 papers receiving 253 citations
Peers
Comparison fields: 5 of 69
- Molecular Biology 99
- Pulmonary and Respiratory Medicine 93
- Oncology 76
- Cancer Research 59
- Pathology and Forensic Medicine 45
Countries citing papers authored by Ruifeng Xue
This map shows the geographic impact of Ruifeng Xue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruifeng Xue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruifeng Xue more than expected).
Fields of papers citing papers by Ruifeng Xue
This network shows the impact of papers produced by Ruifeng Xue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruifeng Xue. The network helps show where Ruifeng Xue may publish in the future.
Co-authorship network of co-authors of Ruifeng Xue
This figure shows the co-authorship network connecting the top 25 collaborators of Ruifeng Xue. A scholar is included among the top collaborators of Ruifeng Xue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruifeng Xue. Ruifeng Xue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 1 | |
| 3 | 3 | |
| 4 | 37 | |
| 5 | 4 | |
| 6 | 4 | |
| 7 | 29 | |
| 8 | 4 | |
| 9 | 13 | |
| 10 | 1 | |
| 11 | 3 | |
| 12 | 5 | |
| 13 | 4 | |
| 14 | 1 | |
| 15 | 15 | |
| 16 | Elevated HMGB1 expression induced by hepatitis B virus X protein promotes epithelial-mesenchymal transition and angiogenesis through STAT3/miR-34a/NF-κB in primary liver cancer. | 32 |
| 17 | 8 | |
| 18 | 24 | |
| 19 | 13 | |
| 20 | [Low-dose methotrexate combined with vinorelbine for inoperable desmoid tumor: efficacy and the prognostic factors]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.